These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 16513447

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
    Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ.
    Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
    [Abstract] [Full Text] [Related]

  • 8. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
    Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ.
    Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
    [Abstract] [Full Text] [Related]

  • 9. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT.
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T, Backman JT, Neuvonen M, Niemi M, Neuvonen PJ.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [Abstract] [Full Text] [Related]

  • 14. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
    Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K.
    Eur J Clin Pharmacol; 2004 Apr; 60(2):109-14. PubMed ID: 15034704
    [Abstract] [Full Text] [Related]

  • 15. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brøsen K.
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [Abstract] [Full Text] [Related]

  • 16. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
    Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ.
    Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
    [Abstract] [Full Text] [Related]

  • 17. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
    Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, Backman JT.
    Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
    Choi JS, Choi I, Choi DH.
    Pharmacol Rep; 2013 Sep; 65(5):1422-30. PubMed ID: 24399740
    [Abstract] [Full Text] [Related]

  • 20. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T, Hisaka A, Sugiyama Y, Ito K.
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.